Modality
Gene Therapy
MOA
IL-23i
Target
KIF18A
Pathway
STING
FLCSU
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
Apr 2017
→ Jan 2029
Phase 2Current
NCT05056710
713 pts·FL
2017-04→2029-01·Terminated
713 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-122.8y awayPh3 Readout· FL
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Termina…
Catalysts
Ph3 Readout
2029-01-12 · 2.8y away
FL
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05056710 | Phase 2/3 | FL | Terminated | 713 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| NUV-2032 | Nuvalent | Preclinical | KIF18A | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | CFTR | |
| DNL-9555 | Denali | Phase 1/2 | KIF18A | |
| Lisoosocimab | Zealand Pharma | Approved | KIF18A |